BR112023022264A2 - Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo - Google Patents

Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo

Info

Publication number
BR112023022264A2
BR112023022264A2 BR112023022264A BR112023022264A BR112023022264A2 BR 112023022264 A2 BR112023022264 A2 BR 112023022264A2 BR 112023022264 A BR112023022264 A BR 112023022264A BR 112023022264 A BR112023022264 A BR 112023022264A BR 112023022264 A2 BR112023022264 A2 BR 112023022264A2
Authority
BR
Brazil
Prior art keywords
methods
steroid
pyrazolyl
dissubstituted
administering
Prior art date
Application number
BR112023022264A
Other languages
English (en)
Portuguese (pt)
Inventor
Senoaji Adiwijaya Bambang
Handan Gunduz-Bruce
Anne Colquhoun Helen
James Doherty
Martin Jonas Jeffrey
Lisa Dunbar Joi
Alfonso Lasser Robert
Ryan Arnold
Jay Kanes Stephen
Vijayveer Bonthapally
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of BR112023022264A2 publication Critical patent/BR112023022264A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112023022264A 2021-04-29 2022-04-29 Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo BR112023022264A2 (pt)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US202163289506P 2021-12-14 2021-12-14
US202163289520P 2021-12-14 2021-12-14
US202263298601P 2022-01-11 2022-01-11
PCT/US2022/026920 WO2022232504A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Publications (1)

Publication Number Publication Date
BR112023022264A2 true BR112023022264A2 (pt) 2024-01-23

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022264A BR112023022264A2 (pt) 2021-04-29 2022-04-29 Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo

Country Status (11)

Country Link
US (1) US20240216395A1 (enExample)
EP (2) EP4768044A2 (enExample)
JP (2) JP2024515829A (enExample)
KR (1) KR20240006026A (enExample)
AU (1) AU2022266680A1 (enExample)
BR (1) BR112023022264A2 (enExample)
CA (1) CA3218072A1 (enExample)
IL (1) IL307991A (enExample)
MX (1) MX2023012727A (enExample)
TW (1) TW202308654A (enExample)
WO (1) WO2022232504A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025508406A (ja) * 2022-02-16 2025-03-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ関連障害を処置するための神経活性ステロイド

Also Published As

Publication number Publication date
EP4329770A1 (en) 2024-03-06
CA3218072A1 (en) 2022-11-03
US20240216395A1 (en) 2024-07-04
WO2022232504A1 (en) 2022-11-03
JP2024515829A (ja) 2024-04-10
JP2025111701A (ja) 2025-07-30
TW202308654A (zh) 2023-03-01
MX2023012727A (es) 2023-11-08
KR20240006026A (ko) 2024-01-12
IL307991A (en) 2023-12-01
EP4768044A2 (en) 2026-07-01
AU2022266680A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
Tirelli et al. Ozone therapy in 65 patients with fibromyalgia: an effective therapy
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2023012727A (es) Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
CL2024003428A1 (es) "formulaciones de anticuerpos anti protofibrillas aß de alta concentración y métodos de uso de las mismas.
BR112020013750A8 (pt) Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
MX2022001403A (es) Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
PH12020551726A1 (en) Treatment of atopic dermatitis
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2021013222A (es) Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
CL2022002885A1 (es) Modulación de enzimas y vías con compuestos de sulfhidrilo y sus derivados
MY193963A (en) Composition for treating joint diseases and kit containing same
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
BR112021016913A2 (pt) Método para tratar doenças relacionadas a tnfa
MX2022006071A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por ccr9 utilizando inhibidores de ccr9 y anticuerpos que bloquean anti-tnf-alfa.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SAGE THERAPEUTICS, LLC (US)

B25G Requested change of headquarter approved

Owner name: SAGE THERAPEUTICS, LLC (US)

B25G Requested change of headquarter approved

Owner name: SAGE THERAPEUTICS, LLC (US)